Sunshine Heart to Present Hemodynamic Data Supporting Mechanism of Action of the C-Pulse System at 2015 Transcatheter Cardiovascular Therapeutics Conference

Sunshine Heart to Present Hemodynamic Data Supporting Mechanism of Action of the C-Pulse System at 2015 Transcatheter Cardiovascular Therapeutics Conference

EDEN PRAIRIE, Minn., Sunshine Heart, Inc. announced today that its flagship C-Pulse® Heart Assist System will be featured in a clinical presentation at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The TCT symposium will take place October 11th -15th in San Francisco, CA at the Moscone Center.

On Wednesday, October 14th, Dr. Dimitrios Georgakopoulos PhD, Sunshine Heart’s Chief Scientific Officer, will present hemodynamic data collected from pre-clinical studies and patients implanted with the C-Pulse device during device optimization and from patients with implantable sensors. These early data presented demonstrate that, in addition to the effects of counterpulsation, C-Pulse may also have a neuromodulation component affecting the parasympathetic and sympathetic nervous systems. Unique insights will be provided from pressure and flow measures obtained in the carotid, coronary and renal circulations and heart rate variability from analysis of individual cardiac cycles. Pilot data applying counterpulsation with C-Pulse to the pulmonary artery in a pre-clinical model of pulmonary hypertension and right heart failure will also be discussed. This oral presentation is entitled “Hemodynamics of C-Pulse: Aortic Counterpulsation and Beyond,” and will be part of the Didactic Symposia: Interventional Heart Failure Therapies session. It will be included in Part 2, Section VII: Acute and Durable Mechanical Circulatory Support at 5:00pm (PDT), Room 3006-3008.

In addition, the company will host an analyst and investor breakfast on Tuesday, October 13th at 7:00am (PDT) at the W Hotel San Francisco. Management will provide a brief corporate update followed by physician presentations listed below:

1. Dr. Dimitrios Georgakopoulos will present the above described data in the context of recent echocardiographic data obtained from patients in the OPTIONS-HF Post-Market Study demonstrating improvements in myocardial remodeling and diastolic function

2. Dr. Leslie W. Miller MD, an investigator in the COUNTER-HF trial, will present recent data on the burden of advanced heart failure on the health care system and the unique role of C-Pulse in this large unmet need. Dr. Miller serves as the Chairman of the Cardiovascular Sciences Department and the Edwards C. Wright Professor of Medicine at the University of South Florida — South Tampa Heart Health. He has been the investigator in over 80 clinical trials in the areas of heart failure, cardiac transplantation and ventricular assist devices and contributed over 285 medical papers. He also serves on the editorial boards and as a reviewer for renowned cardiovascular journals
   
   
3. Dr. William E. Cohn MD, Texas Heart Institute, Houston will provide updates from his long standing collaboration with Sunshine Heart to develop C-Pulse II (CPII), fully implantable device. Recent progress in CPII testing and development will be presented along with plans for a first-in-man study. Dr. Cohn is a prominent cardiothoracic surgeon and has been featured on the cover of US News and World Report. He is Director of the Cullen Cardiovascular Research Laboratory at the Texas Heart Institute and Director of the Center for Technology and Innovation; Associate Director of Laboratory Surgery Research in the Center for Cardiac Support. Dr. Cohn has over 90 US patents granted or pending and 60 international patents for his medical innovations focusing primarily in decreasing the invasiveness of cardiac and vascular surgery, and developing the continuous-flow totally implantable artificial heart. He was awarded a Lifetime Achievement Award for healthcare innovation by the Houston Technology Center.

Source: Sunshine Heart